Elif Bilgin Doğru

Dr. Elif Bilgin Doğru

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
FTFaruk Tas
Faruk Tas
LKLeyla Kilic
Leyla Kilic
EDElif Bilgin Doğru
Elif Bilgin Doğru
SKSerkan Keskin
Serkan Keskin
FSFatma Sen
Fatma Sen
VYVildan Yasasever
Vildan Yasasever

20 August 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
EDElif Bilgin Doğru
Elif Bilgin Doğru
YDYavuz Dizdar
Yavuz Dizdar
EAEce Akşit
Ece Akşit
FUFeyyaz Ural
Feyyaz Ural
OSOner Sanli
Oner Sanli
VYVildan Yasasever
Vildan Yasasever

9 March 2016 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
FTFaruk Tas
Faruk Tas
EDElif Bilgin Doğru
Elif Bilgin Doğru
DTDidem Tastekin
Didem Tastekin
KEKayhan Erturk
Kayhan Erturk
DDDerya Duranyildiz
Derya Duranyildiz
Insulin-like growth factor-1 (IGF-1) and its essential binding protein-3 (IGFBP-3) exhibit significant roles in cellular proliferation, differentiation and apoptosis in numerous malignancies, including lung cancer. The aim of the present study was to determine the clinical roles of the serum IGF-1 and IGFBP-3 levels in lung cancer patients. A total of 80 patients with lung cancer were enrolled in the study. Serum IGF-1 and IGFBP-3 concentrations were determined by ELISA methods. The median age of patients was 58.5 years old, with a range of 36–80 years. The majority of the patients had non-small cell lung cancer (NSCLC) (85%) and metastatic disease (56%). No significant differences were observed in serum IGF-1 levels between lung cancer patients and healthy subjects (P=0.403). However, baseline serum IGFBP-3 levels of the lung cancer patients were significantly lower compared to the control group (P0.05). There was a significant association found between IGF-1 and IGFBP-3 serum levels in lung cancer patients (P<0.001). Neither serum IGF-1 nor IGFBP-3 concentrations were associated with outcome (P=0.552 and P=0.471, respectively). In conclusion, serum concentrations of IGFBP-3 may have a diagnostic predictor in patients with lung cancer compared to serum IGF-1 concentrations. However, predictive and prognostic values of the two serum assays were not observed.

1 October 2012 in Melanoma Research
Verified
Journal Article
Closed access
FTFaruk Tas
Faruk Tas
RCRumeysa Ciftci
Rumeysa Ciftci
LKLeyla Kilic
Leyla Kilic
EDElif Bilgin Doğru
Elif Bilgin Doğru
SKSerkan Keskin
Serkan Keskin
VYVildan Yasasever
Vildan Yasasever
The activation of coagulation and fibrinolysis is frequently found among cancer patients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests for melanoma patients. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin activity (PTA), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were carried out. This prospective study included 61 melanoma patients [stage I–II (n=10), stage III (n=14), stage IV (n=37), M1c (n=26) disease], and 50 healthy controls. It included 34 (56%) men, median age 53 years, range 16–88 years. Over half of the patients (54%) were in the metastatic stage and most of them (70%) had M1c. The plasma level of pretreatment blood coagulation tests including DD, F, APTT, INR levels, and PLT counts showed a statistically significant difference between the patient and the control group (P<0.001 for all, but P=0.049 for INR). The levels of INR, DD, F, and PLT counts were higher and APTT was lower in the melanoma group, whereas the PT and PTA levels did not show any significant difference. There was a significant association between PT, PTA, INR, and PLT levels and the age of the patient. Patients with node metastasis in M0 disease had higher levels of PTA and PLT counts (P=0.002 and 0.048, respectively) and lower levels of PT and INR (P=0.056 and 0.046, respectively). The M1c patients tended to have higher plasma F levels (437 vs. 297 mg/dl, P=0.055) than M1a and M1b patients. The 1-year survival rate for all patients was 70%. In association with distant metastasis, advanced metastatic stage (M1c), elevated lactate dehydrogenase, and erythrocyte sedimentation rate, only elevated plasma F levels had a significantly adverse effect on survival among the coagulation parameters (P=0.031). The 1-year survival rates for patients with high and normal F levels were 58 and 88%, respectively. In conclusion, changes in the coagulation-fibrinolytic system are often present in melanoma and elevation in the plasma F level is associated with decreased survival.

29 July 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
KEKayhan Erturk
Kayhan Erturk
DTDidem Tastekin
Didem Tastekin
MSMurat Serilmez
Murat Serilmez
EDElif Bilgin Doğru
Elif Bilgin Doğru
HBHamza Ugur Bozbey
Hamza Ugur Bozbey
SVSezai Vatansever
Sezai Vatansever